CD8A and neoplasm: Intraperitoneal Olvi-Vec virotherapy, based on a modified vaccinia virus, showed promising safety and clinical activity in platinum-resistant or refractory OC patients through enhancing tumor infiltration of CD8+ T cells and activating tumor-specific T cells in peripheral blood [313].